Q-omics provides the consensus-scored TRAV15 profile across patient tissues and cancer cell-line models. TRAV15 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, TRAV15 is differentially expressed in 3, with the highest sampling consensus in PRAD. Additionally, TRAV15 RNA expression shows 6,058 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight PAAD, PRAD, and STAD as cancer lineages where TRAV15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAV15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAV15 survival associations across molecular data types. TRAV15 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAV15 RNA expression–survival associations across cancer types. High TRAV15 expression shows unfavorable associations in PAAD, STAD, THCA, GBM and LUSC, but favorable associations in LUAD. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for TRAV15 RNA expression.
This table summarizes TRAV15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAV15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAV15 shows lower tumor expression in PRAD and higher tumor expression in KIRC and LUAD. The PRAD box plot shows higher TRAV15 RNA expression in normal versus tumor tissue (log2 FC = −0.041, t-test p = .035).
This table shows molecular features associated with TRAV15 in patient tissues and cancer cell lines. In patient samples, TRAV15 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
